Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
Martin Reck,1 Anders Mellemgaard2 1Department of Thoracic Oncology, Lung Clinic Grosshansdorf, and member of the Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; 2Department of Oncology, Herlev University Hospital, Copenhagen, Denmark Abstract: There remains an...
Guardado en:
Autores principales: | Reck M, Mellemgaard A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ffd7330ca7a744448e8bcf097c506ff0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
por: Rothschild SI
Publicado: (2014) -
A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology
por: Liu H, et al.
Publicado: (2018) -
Clinical development of nintedanib for advanced non-small-cell lung cancer
por: Takeda M, et al.
Publicado: (2015) -
Immunotherapeutic Advances for NSCLC
por: Massafra M, et al.
Publicado: (2021) -
Improving The Oral Absorption Of Nintedanib By A Self-Microemulsion Drug Delivery System: Preparation And In Vitro/In Vivo Evaluation
por: Liu H, et al.
Publicado: (2019)